Sharemaestro Newsreel

Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis

Genelux (NASDAQ:GNLX) Issues Earnings Results

MiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in September

Earnings Call Insights: MiNK Therapeutics (INKT) Q2 2026 MANAGEMENT VIEW * "The second quarter was an important period of execution for MiNK. We moved agenT-797 into a randomized phase two study in patients with acute lung injury and ARDS." (Co-Founder, President, CEO & Director …

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) …

VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18

Wedbush has increased its target price for VOR Biopharma Inc. from $18 to $27. This adjustment reflects a more optimistic outlook on the company's financial prospects by the analyst firm. The article is a brief news update published on Webull.

Capricor Therapeutics Lawsuit Focuses on Deramiocel Disclosures After CAPR Stock Drops

Capricor Therapeutics is facing a federal securities lawsuit alleging that the company failed to disclose crucial information regarding changes in the statistical analysis plan for Deramiocel, its lead therapy candidate. The lawsuit claims that these omissions, particularly concerning FDA interactions and data analysis, led …

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS

Cabaletta Bio (NASDAQ:CABA) reported a quarterly loss of $0.34 per share, exceeding analyst estimates by $0.03. Despite beating estimates, the stock fell to $2.73 during midday trading, significantly below its 52-week high of $4.23. Analysts maintain a "Moderate Buy" rating with an average price …

Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4% - Here's Why

Maplight Therapeutics (NASDAQ:MPLT) saw its stock rise by 6.4% in midday trading on Thursday, despite significantly lower trading volume. The company holds a "Moderate Buy" consensus from analysts with an average price target of $31.17, although it recently reported an earnings per share miss. …

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) recently reached a new 52-week high of $11.45, closing at approximately $11.18 on significant trading volume. Despite missing quarterly EPS expectations by $0.30 with a loss of $0.52 per share, analyst sentiment remains generally positive, holding a "Moderate Buy" consensus and …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.

Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway

Genelux (GNLX), a clinical-stage oncology biotech company, reported a widening net loss of $9.5 million for Q2 2026 and $18.4 million for the first half of 2026, primarily due to increased R&D expenses for its Phase 3 Olvi-Vec cancer trial. Despite a recent $18.5 …

GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary

GENELUX Corp reported its financial results for the six months ended June 30, 2026, showing no revenue, a net loss of $(18.4M), and diluted EPS of $(0.41). The company's net loss worsened compared to the prior year, primarily due to increased clinical and regulatory …

S&P 500 tags an all-time high and these 20 names have helped fuel the rally

[S&P Market Index Concept with Financial Graphs] AlexSecret The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) climbed to a fresh all-time high of 7,816.70 on Thursday, surpassing its prior record of 7,793.68 set on August 5. The benchmark advanced 0.6% for the session and is now up …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ)

Monopar Therapeutics Inc. (MNPR) was downgraded to Neutral from Overweight by Cantor Fitzgerald after a significant rally in its stock price. Cantor Fitzgerald believes the clinical-stage biopharma is now fairly valued following a nearly 90% increase over the past six months. This downgrade led …

Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY

Robbins LLP is urging investors who suffered losses in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) between March 9, 2026, and June 24, 2026, to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline …

Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares

Laurence W. Lytton has reported a beneficial ownership of 5,592,972 shares of Codexis, Inc. (CDXS) common stock, which represents a 5.2% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing with the SEC, indicating an increase in his holdings above …

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with …

Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Ocugen Inc. stock falls Thursday, underperforms market

Ocugen Inc. (OCGN) stock experienced a 3.57% decline on Thursday, closing at $1.35. This fall occurred despite a positive trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The decrease in Ocugen's stock price broke …

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 3.28% to $10.08, marking its third consecutive day of gains. This performance occurred on a strong trading day where the NASDAQ Composite Index increased by 0.81% and the Dow Jones Industrial Average rose by …

Curis prices $5.6 million public offering at $1.50 per share By Investing.com

Curis Inc. (NASDAQ:CRIS) has priced a public offering of 3,733,334 shares of common stock and warrants at $1.50 per share, aiming to raise approximately $5.6 million. The offering includes warrants exercisable at $1.75 per share, expiring in five years, and pre-funded warrants for some …

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

Mirum Pharmaceuticals (MIRM) saw its stock drop 6.4% despite raising its 2026 net product sales guidance, due to reporting significantly wider net losses in the second quarter of 2026. The company highlighted progress with breakthrough therapy designation for volixibat and potential launch timing for …

Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management

Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds …

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

Three analysts have issued bullish sentiments on healthcare companies Immunic (IMUX), Legend Biotech (LEGN), and Sagimet Biosciences, Inc. Class A (SGMT). William Blair reiterated a Buy rating on Immunic, H.C. Wainwright reiterated a Buy on Legend Biotech with a $65.00 price target, and Wedbush …

Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4%

Short interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) significantly increased by 223.4% to 135,370 shares as of July 31st. This represents approximately 0.6% of the company's shares outstanding and a days-to-cover ratio of 0.9 days. Despite mixed analyst sentiment with a consensus "Hold" …

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics reported strong second-quarter 2026 financial results with $101.9 million in consolidated revenue and $26.0 million in net income, driven by robust sales of DefenCath and contributions from the acquired Melinta portfolio. The company maintained its full-year 2026 revenue guidance and raised its …

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates

ProQR Therapeutics NV (NASDAQ: PRQR) reported second-quarter earnings per share that beat analyst estimates by €0.03, coming in at €-0.080 against an estimate of €-0.114. The company's revenue also surpassed expectations, reaching €8.76 million compared to the consensus estimate of €3.97 million. Despite these …

Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios

Janus Henderson Group Ltd. has disclosed an 8.4% passive ownership stake in Protara Therapeutics, Inc. (TARA) through its asset managers, holding 4,696,709 shares of common stock. These shares are managed on behalf of client accounts, referred to as Managed Portfolios, with Janus Henderson exercising …

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share …

Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates